(a) Conventional chimeric VLP vaccine requires first producing fusion viral proteins conjugated with self-assembling modules by challengeable gene design and expression, and then carrying out ...

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug ...

Attachment of a bacterial protein to the tips of phage tails produces non-infectious, tailless phages. “Many of these bacterial systems have been shown to be the evolutionary origin of different human ...

A research team led by Professor Seung Soo Oh and Dr. Hyesung Jo from the Department of Materials Science and Engineering at POSTECH (Pohang University of Science and Technology) has developed an ...

Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells Nurix to receive a $60 ...